AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation device based on electrical stimulation
Description: Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
Study NCT04906694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-DROPS
Description: COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
Study NCT04906694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study NCT05087108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsciPulse system
Description: The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
Study NCT05087108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Therapy 1
Description: The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
Study NCT06325111 — intervention group
Intervention type: OTHER
Intervention: Determinants of T1D glycaemic control
Description: DNA genotyping, microbiome, DNA methylation and microRNAs analysis
Study NCT05530577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide (subcutaneous)
Study NCT05530577 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham/placebo
Description: Sham subcutaneous injection
Study NCT03816228 — intervention group
Intervention type: DRUG
Intervention: F 18 T807 Flortaucipir
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT04745663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.3%
Description: Low concentration iodine
Study NCT04745663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine 5%
Description: Standard concentration iodine
Study NCT05263609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
Study NCT05263609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
Study NCT04157426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous electrolysis
Description: Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
Study NCT06293664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: α-MSH infusion
Description: Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
Study NCT06293664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solutions
Description: Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
Study NCT04157426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
Study NCT03769688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervicovaginal secretions
Description: Same as arm descriptions
Study NCT03769688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Description: 5 day course of vaginal MetroGel will be used prior to VMT intervention.
Study NCT03769688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole gel
Description: 5 day course of vaginal MetroGel will be used prior to VMT intervention.
Study NCT03769688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening tests
Description: Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
Study NCT03769688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Screening tests
Description: Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
Study NCT03769688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities restriction
Description: Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
Study NCT03769688 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Activities restriction
Description: Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
Study NCT03769688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline placebo
Description: This will be administered as a placebo in place of cervicovaginal secretions
Study NCT05087108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Refence Therapy 2
Description: The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
Study NCT06131788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational hand hygiene intervention
Description: The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
Study NCT05090826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model ZFR00V
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
Study NCT06249256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fast CAR T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
Study NCT06317077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PAP therapy setting
Description: Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
Study NCT06317077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exclusive use of Löwenstein Medical full face masks
Description: Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
Study NCT06391957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina supplement
Description: Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.
Study NCT06391957 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
Study NCT06391957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
Study NCT06391957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
Study NCT05228106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [68Ga]-PSMA-617
Description: The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
Study NCT05138783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study NCT05138783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study NCT06468293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychological support
Description: Psychological support intervention
Study NCT06437418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasonography.
Description: Evaluate the gallbladder ejection fraction (EF)
Study NCT05291455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: lacosamide will be given
Study NCT05291455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: phenobarbital will be given
Study NCT04628104 — intervention group
Intervention type: RADIATION
Intervention: cardiac magnetic resonance
Description: o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation
Study NCT06561152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)
Study NCT06561152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD)
Description: Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)
Study NCT06561152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)
Study NCT06453031 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric Ischemic Preconditioning Before Esophagectomy
Description: Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
Study NCT06348095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Study NCT06348095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Study NCT05173090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery
Description: Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
Study NCT05173090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery
Description: Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
Study NCT05469919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib taken orally
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution_#2
Description: 40cc
Study NCT06488664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-068
Description: GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.
Study NCT06488664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara®
Description: Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
Study NCT05589987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: power mobility
Description: Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded.
Study NCT05641935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV
Study NCT05641935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS
Study NCT05641935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05641935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05641935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Review electronic medical record
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution_#2
Description: 40cc
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Description: 10cc
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Description: 10cc
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Description: 10cc
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#2
Description: 20cc
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#2
Description: 20cc
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketorolac
Description: 15mg
Study NCT05062356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 15mg
Study NCT05194150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-diffractive monofocal IOL
Description: Rayone EMV
Study NCT04825028 — intervention group
Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.
Study NCT05194150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard EDOF IOL
Description: Acrysof IQ Vivity
Study NCT05129956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien Emprint Ablation System with Thermosphere Technology
Description: The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
Study NCT06172413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min.
Study NCT06172413 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: Sham tACS
Study NCT05669222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAST Technique
Description: The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
Study NCT05669222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
Study NCT05669222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
Study NCT05859113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ziacom Galaxy dental implant with internal connical prosthetic connection
Description: Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
Study NCT05859113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ziacom Zinic dental implant with internal hexagonal prosthetic connection
Description: Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
Study NCT06145919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Description: The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
Study NCT04859335 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: gammaknife radiosurgery
Description: Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
Study NCT06145919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Description: In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
Study NCT05880147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consent App
Description: Family will receive their study information and consent form in an app on a tablet